Doxycycline Hyclate | US Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Doxycycline Hyclate
US Patents

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

With Fermion, start the journey of your innovative API.

Contact Supplier

Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Doxycycline Hyclate

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

33 API Suppliers, 17 USDMF, 10 CEP/COS, 1 JDMF, 2 EU WC, 2 KDMF, 15 NDC API, 1 VMF, 17 Listed Suppliers, $ API Reference Price

33 API Suppliers
17 USDMF
10 CEP/COS
1 JDMF
2 EU WC
2 KDMF
15 NDC API
1 VMF
17 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

26 Drugs in Development

26 Drugs in Development

FINISHED DOSAGE FORMULATIONS

222 FDF Dossiers, 182 FDA Orange Book, 2 Europe, 15 Canada, 23 Listed Dossiers

222 FDF Dossiers
182 FDA Orange Book
2 Europe
15 Canada
23 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 150MG BASE, TABLET;ORAL - EQ 75MG BASE, TABLET;ORAL - EQ 100MG BASE, CAPSULE;ORAL - EQ 100MG BASE, CAPSULE;ORAL - EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, DELAYED RELEASE;ORAL - EQ 100MG BASE, CAPSULE, DELAYED RELEASE;ORAL - EQ 75MG BASE, SYSTEM, EXTENDED RELEASE;PERIODONTAL - 50MG, TABLET, DELAYED RELEASE;ORAL - EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 120MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 150MG BASE, TABLET, DELAYED RELEASE;ORAL - EQ 200MG BASE, TABLET, DELAYED RELEASE;ORAL - EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 60MG BASE, TABLET, DELAYED RELEASE;ORAL - EQ 75MG BASE, TABLET, DELAYED RELEASE;ORAL - EQ 80MG BASE

TABLET;ORAL - EQ 150MG BASE
TABLET;ORAL - EQ 75MG BASE
TABLET;ORAL - EQ 100MG BASE
CAPSULE;ORAL - EQ 100MG BASE
CAPSULE;ORAL - EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE, DELAYED RELEASE;ORAL - EQ 100MG BASE
CAPSULE, DELAYED RELEASE;ORAL - EQ 75MG BASE
SYSTEM, EXTENDED RELEASE;PERIODONTAL - 50MG
TABLET, DELAYED RELEASE;ORAL - EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, DELAYED RELEASE;ORAL - EQ 120MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, DELAYED RELEASE;ORAL - EQ 150MG BASE
TABLET, DELAYED RELEASE;ORAL - EQ 200MG BASE
TABLET, DELAYED RELEASE;ORAL - EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, DELAYED RELEASE;ORAL - EQ 60MG BASE
TABLET, DELAYED RELEASE;ORAL - EQ 75MG BASE
TABLET, DELAYED RELEASE;ORAL - EQ 80MG BASE

RELATED EXCIPIENT COMPANIES

3 Rochem International Inc, 17 SPI Pharma, 2 Seqens, 9 DKSH, 7 Faran Shimi Pharmaceutical, 8 Boai NKY Pharmaceuticals Ltd, 14 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 4 ACG Worldwide, 12 Actylis, 2 Aeon Procare, 1 Alcedo Pharmachem, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 33 BASF, 1 Clariant, 11 Corel Pharma Chem, 7 DFE Pharma, 3 Finar, 12 Gangwal Chemicals, 8 Ideal Cures Pvt Ltd, 5 Ingredion Pharma Solutions, 40 Kerry, 5 Kima Chemical, 6 Lonza Capsugel, 22 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nomisma Healthcare, 4 Novo Excipients, 4 Pharmatrans-Sanaq, 8 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 29 Roquette, 14 Seppic, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 12 Sigachi Industries, 4 The Dow Chemical Company, 2 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem, 1 Vertellus, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

103 Fillers, Diluents & Binders, 65 Coating Systems & Additives, 48 Direct Compression, 42 Disintegrants & Superdisintegrants, 39 Thickeners and Stabilizers, 36 Controlled & Modified Release, 33 Granulation, 29 Solubilizers, 29 Parenteral, 28 Film Formers & Plasticizers, 24 Taste Masking, 22 Lubricants & Glidants, 22 Co-Processed Excipients, 19 Topical, 18 Chewable & Orodispersible Aids, 9 Empty Capsules, 8 Emulsifying Agents, 8 Rheology Modifiers, 8 API Stability Enhancers, 5 Surfactant & Foaming Agents, 5 Coloring Agents, 4 Vegetarian Capsules, 1 Soft Gelatin

103 Fillers, Diluents & Binders
65 Coating Systems & Additives
48 Direct Compression
42 Disintegrants & Superdisintegrants
39 Thickeners and Stabilizers
36 Controlled & Modified Release
33 Granulation
29 Solubilizers
29 Parenteral
28 Film Formers & Plasticizers
24 Taste Masking
22 Lubricants & Glidants
22 Co-Processed Excipients
19 Topical
18 Chewable & Orodispersible Aids
9 Empty Capsules
8 Emulsifying Agents
8 Rheology Modifiers
8 API Stability Enhancers
5 Surfactant & Foaming Agents
5 Coloring Agents
4 Vegetarian Capsules
1 Soft Gelatin

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 50 NEWS #PharmaBuzz

1 DATA COMPILATION #PharmaFlow
50 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 18 Finished Drug Prices

1 US Medicaid Prescriptions
18 Finished Drug Prices

MARKET PLACE

63 APIs, 1 FDF Dossiers

63 APIs
1 FDF Dossiers

PATENTS & EXCLUSIVITIES

14 US Patents

14 US Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 1 USP, 1 Others

2 EDQM
1 USP
1 Others

$ API Ref.Price (USD/KG) : 81 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

14 All

01 14MAYNE PHARMA

filter Patent Number Reset all filters

14 All

01 88715724

02 29295652

03 29446057

04 29511031

filter API Patent Reset all filters

14 All

01 14Blank

filter FDF Patent Reset all filters

14 All

01 14Y

filter Expiration Date Reset all filters

14 All

01 82028-02-03

02 42034-10-23

03 22034-12-23

Product Main Page

01

MAYNE PHARMA

DOXYCYCLINE HYCLATE

Antibody Engineering

Not Confirmed

MAYNE PHARMA

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2034-10-23

DOXYCYCLINE HYCLATE

US Patent Number : 9295652

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 50795

Patent Use Code : U-918

Delist Requested :

Patent Use Description : TO TREAT OR PREVENT IN...

Patent Expiration Date : 2034-10-23

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

MAYNE PHARMA

DOXYCYCLINE HYCLATE

Antibody Engineering

Not Confirmed

MAYNE PHARMA

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2034-10-23

DOXYCYCLINE HYCLATE

US Patent Number : 9295652

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 50795

Patent Use Code : U-918

Delist Requested :

Patent Use Description : TO TREAT OR PREVENT IN...

Patent Expiration Date : 2034-10-23

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

MAYNE PHARMA

DOXYCYCLINE HYCLATE

Antibody Engineering

Not Confirmed

MAYNE PHARMA

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-02-03

DOXYCYCLINE HYCLATE

US Patent Number : 8715724

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 50795

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2028-02-03

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

MAYNE PHARMA

DOXYCYCLINE HYCLATE

Antibody Engineering

Not Confirmed

MAYNE PHARMA

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-02-03

DOXYCYCLINE HYCLATE

US Patent Number : 8715724

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 50795

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2028-02-03

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

MAYNE PHARMA

DOXYCYCLINE HYCLATE

Antibody Engineering

Not Confirmed

MAYNE PHARMA

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-02-03

DOXYCYCLINE HYCLATE

US Patent Number : 8715724

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 50795

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2028-02-03

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

MAYNE PHARMA

DOXYCYCLINE HYCLATE

Antibody Engineering

Not Confirmed

MAYNE PHARMA

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-02-03

DOXYCYCLINE HYCLATE

US Patent Number : 8715724

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 50795

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2028-02-03

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

MAYNE PHARMA

DOXYCYCLINE HYCLATE

Antibody Engineering

Not Confirmed

MAYNE PHARMA

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-02-03

DOXYCYCLINE HYCLATE

US Patent Number : 8715724

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 50795

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2028-02-03

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

MAYNE PHARMA

DOXYCYCLINE HYCLATE

Antibody Engineering

Not Confirmed

MAYNE PHARMA

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2034-10-23

DOXYCYCLINE HYCLATE

US Patent Number : 9511031

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 50795

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2034-10-23

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

09

MAYNE PHARMA

DOXYCYCLINE HYCLATE

Antibody Engineering

Not Confirmed

MAYNE PHARMA

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-02-03

DOXYCYCLINE HYCLATE

US Patent Number : 8715724

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 50795

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2028-02-03

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

10

MAYNE PHARMA

DOXYCYCLINE HYCLATE

Antibody Engineering

Not Confirmed

MAYNE PHARMA

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-02-03

DOXYCYCLINE HYCLATE

US Patent Number : 8715724

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 50795

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2028-02-03

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

1
2

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?